122 related articles for article (PubMed ID: 38010733)
21. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.
Chen X; Bahrami A; Pappo A; Easton J; Dalton J; Hedlund E; Ellison D; Shurtleff S; Wu G; Wei L; Parker M; Rusch M; Nagahawatte P; Wu J; Mao S; Boggs K; Mulder H; Yergeau D; Lu C; Ding L; Edmonson M; Qu C; Wang J; Li Y; Navid F; Daw NC; Mardis ER; Wilson RK; Downing JR; Zhang J; Dyer MA;
Cell Rep; 2014 Apr; 7(1):104-12. PubMed ID: 24703847
[TBL] [Abstract][Full Text] [Related]
22. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Perry JA; Kiezun A; Tonzi P; Van Allen EM; Carter SL; Baca SC; Cowley GS; Bhatt AS; Rheinbay E; Pedamallu CS; Helman E; Taylor-Weiner A; McKenna A; DeLuca DS; Lawrence MS; Ambrogio L; Sougnez C; Sivachenko A; Walensky LD; Wagle N; Mora J; de Torres C; Lavarino C; Dos Santos Aguiar S; Yunes JA; Brandalise SR; Mercado-Celis GE; Melendez-Zajgla J; Cárdenas-Cardós R; Velasco-Hidalgo L; Roberts CW; Garraway LA; Rodriguez-Galindo C; Gabriel SB; Lander ES; Golub TR; Orkin SH; Getz G; Janeway KA
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5564-73. PubMed ID: 25512523
[TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
25. Germ-line genetic variation of TP53 in osteosarcoma.
Savage SA; Burdett L; Troisi R; Douglass C; Hoover RN; Chanock SJ;
Pediatr Blood Cancer; 2007 Jul; 49(1):28-33. PubMed ID: 17096406
[TBL] [Abstract][Full Text] [Related]
26. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.
Das S; Idate R; Regan DP; Fowles JS; Lana SE; Thamm DH; Gustafson DL; Duval DL
Commun Biol; 2021 Oct; 4(1):1178. PubMed ID: 34635775
[TBL] [Abstract][Full Text] [Related]
27. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
[No Abstract] [Full Text] [Related]
28. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.
Yoon H; Liyanarachchi S; Wright FA; Davuluri R; Lockman JC; de la Chapelle A; Pellegata NS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15632-7. PubMed ID: 12438652
[TBL] [Abstract][Full Text] [Related]
29. Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas.
Patiño-García A; Piñeiro ES; Díez MZ; Iturriagagoitia LG; Klüssmann FA; Ariznabarreta LS
J Pediatr Hematol Oncol; 2003 May; 25(5):362-7. PubMed ID: 12759621
[TBL] [Abstract][Full Text] [Related]
30. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
[TBL] [Abstract][Full Text] [Related]
31. Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.
Yang J; Annala M; Ji P; Wang G; Zheng H; Codgell D; Du X; Fang Z; Sun B; Nykter M; Chen K; Zhang W
J Hematol Oncol; 2014 Oct; 7():76. PubMed ID: 25300797
[TBL] [Abstract][Full Text] [Related]
32. Correlation between apoptosis and TP53 status in osteosarcoma.
Pompetti F; Stuppia L; Gatta V; Calabrese G; Gamberi G; Benassi MS; Picci P; Palka G
Cancer Genet Cytogenet; 1998 Sep; 105(2):177-81. PubMed ID: 9723038
[TBL] [Abstract][Full Text] [Related]
33. Germline TP53 variants and susceptibility to osteosarcoma.
Mirabello L; Yeager M; Mai PL; Gastier-Foster JM; Gorlick R; Khanna C; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Andrulis IL; Wunder JS; Gokgoz N; Barkauskas DA; Zhang X; Vogt A; Jones K; Boland JF; Chanock SJ; Savage SA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25896519
[TBL] [Abstract][Full Text] [Related]
34. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
35. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].
Gao DL; Dong RF; Liu WF; Gong LH; Xu HR; Niu XH; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):370-375. PubMed ID: 36973198
[No Abstract] [Full Text] [Related]
36. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
37. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
38. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
39. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.
Jin W; Zhou L; Yan B; Yan L; Liu F; Tong P; Yu W; Dong X; Xie L; Zhang J; Xu Y; Li C; Yuan Q; Shan L; Efferth T
J Cell Mol Med; 2018 Sep; 22(9):4423-4436. PubMed ID: 29993186
[TBL] [Abstract][Full Text] [Related]
40. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.
Shaul E; Roth M; Lo Y; Geller DS; Hoang B; Yang R; Malkin D; Gorlick R; Gill J
Cancer; 2018 Mar; 124(6):1242-1250. PubMed ID: 29313943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
